AGENUS INC Cost of Revenue
AGENUS INC (AGEN) reported Cost of Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-07
- AGENUS INC cost of revenue for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC cost of revenue for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC cost of revenue for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC cost of revenue for the quarter ending 2025-09-30 was $642.00K, a 339.73% increase year-over-year.
- AGENUS INC cost of revenue for fiscal 2025 was $1.02M, a 110.29% increase from fiscal 2024.
- AGENUS INC cost of revenue for fiscal 2024 was $486.00K, a 84.38% decline from fiscal 2023.
- AGENUS INC cost of revenue for fiscal 2023 was $3.11M, a 70.56% decline from fiscal 2022.
- AGENUS INC cost of revenue for fiscal 2022 was $10.57M, a 204.55% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-07 | $0.00 10-Q · filed 2026-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-08-07 | $642.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $642.00K derived: sum of 3 quarters · filed 2026-05-11 | $885.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $642.00K derived: sum of 2 quarters · filed 2026-03-16 | $885.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.02M 10-K · filed 2026-03-16 |
| 2025-09-30 | $642.00K 10-Q · filed 2025-11-10 | $885.00K derived: sum of 2 quarters · filed 2026-08-07 | $1.02M 10-Q · filed 2025-11-10 | $1.14M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $243.00K 10-Q · filed 2026-08-07 | $380.00K 10-Q · filed 2026-08-07 | $498.00K derived: sum of 3 quarters · filed 2026-08-07 | $644.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $137.00K 10-Q · filed 2026-05-11 | $255.00K derived: sum of 2 quarters · filed 2026-05-11 | $401.00K derived: sum of 3 quarters · filed 2026-05-11 | $516.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $264.00K derived: sum of 2 quarters · filed 2026-03-16 | $379.00K derived: sum of 3 quarters · filed 2026-03-16 | $486.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $146.00K 10-Q · filed 2025-11-10 | $261.00K derived: sum of 2 quarters · filed 2025-11-10 | $368.00K 10-Q · filed 2025-11-10 | $628.00K derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-06-30 | $115.00K 10-Q · filed 2025-08-11 | $222.00K 10-Q · filed 2025-08-11 | $482.00K derived: sum of 3 quarters · filed 2026-03-16 | $785.00K derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-03-31 | $107.00K 10-Q · filed 2025-05-12 | $367.00K derived: sum of 2 quarters · filed 2026-03-16 | $670.00K derived: sum of 3 quarters · filed 2026-03-16 | $924.00K derived: sum of 4 quarters · filed 2026-03-16 |
| 2023-12-31 | $260.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $563.00K derived: sum of 2 quarters · filed 2026-03-16 | $817.00K derived: sum of 3 quarters · filed 2026-03-16 | $3.11M 10-K · filed 2026-03-16 |
| 2023-09-30 | $303.00K 10-Q · filed 2024-11-12 | $557.00K derived: sum of 2 quarters · filed 2024-11-12 | $2.85M 10-Q · filed 2024-11-12 | $10.54M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $254.00K 10-Q · filed 2024-08-08 | $2.55M 10-Q · filed 2024-08-08 | $10.24M derived: sum of 3 quarters · filed 2025-03-17 | $10.55M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $2.29M 10-Q · filed 2024-05-07 | $9.99M derived: sum of 2 quarters · filed 2025-03-17 | $10.29M derived: sum of 3 quarters · filed 2025-03-17 | $12.32M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $7.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $8.00M derived: sum of 2 quarters · filed 2025-03-17 | $10.03M derived: sum of 3 quarters · filed 2025-03-17 | $10.57M 10-K · filed 2025-03-17 |
| 2022-09-30 | $308.00K 10-Q · filed 2023-11-09 | $2.33M derived: sum of 2 quarters · filed 2023-11-09 | $2.88M 10-Q · filed 2023-11-09 | $3.76M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $2.02M 10-Q · filed 2023-08-08 | $2.57M 10-Q · filed 2023-08-08 | $3.45M derived: sum of 3 quarters · filed 2024-03-14 | $4.26M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $543.00K 10-Q · filed 2023-05-09 | $1.42M derived: sum of 2 quarters · filed 2024-03-14 | $2.24M derived: sum of 3 quarters · filed 2024-03-14 | $2.91M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $881.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.70M derived: sum of 2 quarters · filed 2024-03-14 | $2.37M derived: sum of 3 quarters · filed 2024-03-14 | $3.47M 10-K · filed 2024-03-14 |
| 2021-09-30 | $817.00K 10-Q · filed 2022-11-08 | $1.48M derived: sum of 2 quarters · filed 2022-11-08 | $2.59M 10-Q · filed 2022-11-08 | $3.39M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $667.00K 10-Q · filed 2022-08-09 | $1.77M 10-Q · filed 2022-08-09 | $2.58M derived: sum of 3 quarters · filed 2023-03-16 | $3.49M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $1.10M 10-Q · filed 2022-05-10 | $1.91M derived: sum of 2 quarters · filed 2023-03-16 | $2.82M derived: sum of 3 quarters · filed 2023-03-16 | $3.45M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $804.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.72M derived: sum of 2 quarters · filed 2023-03-16 | $2.35M derived: sum of 3 quarters · filed 2023-03-16 | $2.35M 10-K · filed 2023-03-16 |
| 2020-09-30 | $911.00K 10-Q · filed 2021-11-09 | $1.54M derived: sum of 2 quarters · filed 2021-11-09 | $1.54M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $634.00K 10-Q · filed 2021-08-09 | $634.00K 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |